Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Balance Sheet
6 Sheets · Starting from 2024In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Assets | - - | 109.00 | 412.00 | 515.00 | 405.00 | 666.00 | |
|
Current
|
- - | 109.00 | 409.00 | 512.00 | 404.00 | 665.00 | |
| Cash And Equivalents | - - | 100.00 | 400.00 | 493.00 | 376.00 | 635.00 | |
| Assets | - - | 109.00 | 412.00 | 515.00 | 405.00 | 666.00 | |
| Accounts Receivables (AR) | - - | - - | - - | -11.00 | 11.00 | -4.00 | |
| Inventory | - - | - - | - - | - - | - - | - - | |
| Short Term Investments | - - | - - | - - | - - | - - | - - | |
| Other Current Assets | - - | 5.00 | 8.00 | 6.00 | 26.00 | 24.00 | |
|
Non Current
|
- - | - - | 3.00 | 2.00 | 1.00 | - - | |
| Property, Plant, Equipment (Net) | - - | - - | 3.00 | 2.00 | 1.00 | - - | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | |
| Other Non Current Assets | - - | - - | - - | - - | - - | - - | |
| Liabilities | - - | 15.00 | 21.00 | 45.00 | 43.00 | 48.00 | |
|
Current
|
- - | 15.00 | 18.00 | 44.00 | 43.00 | 48.00 | |
| Accounts Payable | - - | - - | 1.00 | 16.00 | -17.00 | 5.00 | |
| Short Term Debt | - - | 3.00 | 1.00 | 1.00 | 1.00 | - - | |
| Deferred Revenue | - - | -3.00 | - - | - - | - - | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | - - | 14.00 | 15.00 | 24.00 | 40.00 | 41.00 | |
|
Non Current
|
- - | 14.00 | 2.00 | 1.00 | - - | - - | |
| Long Term Debt | - - | - - | 2.00 | 1.00 | - - | - - | |
| Leasing Obligations | - - | - - | 3.00 | 2.00 | 1.00 | - - | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | - - | 14.00 | - - | - - | - - | - - | |
| Equity | - - | 94.00 | 391.00 | 469.00 | 362.00 | 617.00 | |
| Stockholders' Equity | - - | 94.00 | 391.00 | 469.00 | 362.00 | 617.00 | |
| Retained Earnings | - - | -91.00 | -198.00 | -355.00 | -566.00 | -825.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | |
| Profit | - - | -66.00 | -107.00 | -156.00 | -210.00 | -259.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | - - | 185.00 | 590.00 | 824.00 | 927.00 | 1,441.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - | 1.00 |